164 related articles for article (PubMed ID: 15801922)
41. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
Ratziu V; Caldwell S; Neuschwander-Tetri BA
Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
[TBL] [Abstract][Full Text] [Related]
42. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.
Bugianesi E; Marzocchi R; Villanova N; Marchesini G
Best Pract Res Clin Gastroenterol; 2004 Dec; 18(6):1105-16. PubMed ID: 15561641
[TBL] [Abstract][Full Text] [Related]
43. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease.
Dohil R; Schmeltzer S; Cabrera BL; Wang T; Durelle J; Duke KB; Schwimmer JB; Lavine JE
Aliment Pharmacol Ther; 2011 May; 33(9):1036-44. PubMed ID: 21395631
[TBL] [Abstract][Full Text] [Related]
44. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Sponseller CA; Hampton K; Bacon BR
J Hepatol; 2003 Apr; 38(4):434-40. PubMed ID: 12663234
[TBL] [Abstract][Full Text] [Related]
45. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.
Haukeland JW; Konopski Z; Eggesbø HB; von Volkmann HL; Raschpichler G; Bjøro K; Haaland T; Løberg EM; Birkeland K
Scand J Gastroenterol; 2009; 44(7):853-60. PubMed ID: 19811343
[TBL] [Abstract][Full Text] [Related]
46. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials.
Jalali M; Rahimlou M; Mahmoodi M; Moosavian SP; Symonds ME; Jalali R; Zare M; Imanieh MH; Stasi C
Pharmacol Res; 2020 Sep; 159():104799. PubMed ID: 32278041
[TBL] [Abstract][Full Text] [Related]
47. Metformin in the treatment of patients with non-alcoholic steatohepatitis.
Uygun A; Kadayifci A; Isik AT; Ozgurtas T; Deveci S; Tuzun A; Yesilova Z; Gulsen M; Dagalp K
Aliment Pharmacol Ther; 2004 Mar; 19(5):537-44. PubMed ID: 14987322
[TBL] [Abstract][Full Text] [Related]
48. Metformin in non-alcoholic steatohepatitis.
Marchesini G; Brizi M; Bianchi G; Tomassetti S; Zoli M; Melchionda N
Lancet; 2001 Sep; 358(9285):893-4. PubMed ID: 11567710
[TBL] [Abstract][Full Text] [Related]
49. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.
Lavine JE; Schwimmer JB; Molleston JP; Scheimann AO; Murray KF; Abrams SH; Rosenthal P; Sanyal AJ; Robuck PR; Brunt EM; Unalp A; Tonascia J;
Contemp Clin Trials; 2010 Jan; 31(1):62-70. PubMed ID: 19761871
[TBL] [Abstract][Full Text] [Related]
50. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL.
Oliveira CP; Cotrim HP; Stefano JT; Siqueira ACG; Salgado ALA; Parise ER
Arq Gastroenterol; 2019 Aug; 56(2):184-190. PubMed ID: 31460584
[TBL] [Abstract][Full Text] [Related]
51. [Treatment of non-alcoholic steatohepatitis].
Fehér J; Hagymási K
Orv Hetil; 2004 Mar; 145(12):631-4. PubMed ID: 15119118
[No Abstract] [Full Text] [Related]
52. Nonalcoholic steatohepatitis: role of leptin in pathogenesis and benefits of metformin in treatment.
Kadayifçi A
Am J Gastroenterol; 2003 Oct; 98(10):2330; author reply 2330-1. PubMed ID: 14572592
[No Abstract] [Full Text] [Related]
53. METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study.
van der Aa MP; Elst MA; van Mil EG; Knibbe CA; van der Vorst MM
Trials; 2014 Jun; 15():207. PubMed ID: 24899137
[TBL] [Abstract][Full Text] [Related]
54. Metformin in non-alcoholic steatohepatitis.
Urso R; Visco-Comandini U
Lancet; 2002 Jan; 359(9303):355-6. PubMed ID: 11830232
[No Abstract] [Full Text] [Related]
55. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial.
Shavakhi A; Minakari M; Firouzian H; Assali R; Hekmatdoost A; Ferns G
Int J Prev Med; 2013 May; 4(5):531-7. PubMed ID: 23930163
[TBL] [Abstract][Full Text] [Related]
56. Effect of Metformin on Handgrip Strength, Gait Speed, Myostatin Serum Level, and Health-related Quality of Life: A Double Blind Randomized Controlled Trial among Non-diabetic Pre-frail Elderly Patients.
Laksmi PW; Setiati S; Tamin TZ; Soewondo P; Rochmah W; Nafrialdi N; Prihartono J
Acta Med Indones; 2017 Apr; 49(2):118-127. PubMed ID: 28790226
[TBL] [Abstract][Full Text] [Related]
57. Metformin in nonalcoholic steatohepatitis: a randomized controlled trial.
Kazemi R; Aduli M; Sotoudeh M; Malekzadeh R; Seddighi N; Sepanlou SG; Merat S
Middle East J Dig Dis; 2012 Jan; 4(1):16-22. PubMed ID: 24829630
[TBL] [Abstract][Full Text] [Related]
58. Metformin superior to low‑fat diet for the treatment of patients with nonalcoholic fatty liver disease and/or steatohepatitis.
Resuli B; Demiraj V; Babameto A; Sema K; Malaj V
Pol Arch Med Wewn; 2012; 122 Suppl 1():68-71. PubMed ID: 23222203
[No Abstract] [Full Text] [Related]
59. [Drug therapy for nonalcoholic fatty liver disease].
Shen W
Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):139. PubMed ID: 15727706
[No Abstract] [Full Text] [Related]
60. Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Corey KE; Chalasani N
Hepatology; 2011 Nov; 54(5):1503-5. PubMed ID: 21953015
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
